Biodexa Pharmaceuticals PLC
BDRX7.040USD
+0.130+1.88%
收盘 08/14, 16:00（美东）报价延迟15分钟
47.07B总市值
--市盈率 TTM
关于 Biodexa Pharmaceuticals PLC 公司
Biodexa Pharmaceuticals PLC 是一家位于英国的临床阶段生物制药公司。该公司正在开发一系列产品，用于治疗尚未满足医疗需求的疾病。其技术包括 Biodexa Pharmaceuticals Q-Sphera、MidaCore 和 MidaSolve。Q-Sphera 技术专注于长效注射剂，使用专有的三维 (3D) 打印技术将药物封装到具有精确特性的生物可吸收聚合物微球中。MidaCore 技术平台使用超小金纳米颗粒 (GNP) 药物偶联物。MidaSolve Nano Inclusion 技术可溶解具有最小溶解度生物氢 (pH) 潜力的分子，从而扩展可用的给药途径，包括直接向肿瘤递送。其产品线包括 MTX110、MTD201、MTD211（精神分裂症、MDD）、MTX223 和 MTD217。
公司简介
公司代码BDRX
公司名称Biodexa Pharmaceuticals PLC
上市日期Dec 08, 2014
CEOMr. Stephen A. Stamp
员工数量- -
证券类型Depository Receipt
年结日Dec 08
公司地址1 Caspian Point
城市ABINGDON
上市交易所NASDAQ Capital Market Consolidated
国家United Kingdom
邮编CF10 4DQ
电话4401235888300
网址https://www.biodexapharma.com/
公司代码BDRX
上市日期Dec 08, 2014
CEOMr. Stephen A. Stamp
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Sijmen (Sijmen) De Vries, M.D.
Dr. Sijmen (Sijmen) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Sijmen (Sijmen) De Vries, M.D.
Dr. Sijmen (Sijmen) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
单位: GBP更新时间: 7月6日 周日
单位: GBP更新时间: 7月6日 周日
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
暂无数据
地区GBP
名称
营收
占比
Belgium
381.00K
100.00%
业务
地区
暂无数据
股东统计
更新时间: 7月11日 周五
更新时间: 7月11日 周五
持股股东
股东类型
持股股东
持股股东
占比
Cavalry Fund I Management, LLC
2.83%
Brio Capital Management LLC
2.71%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
Melior Pharmaceuticals I, Inc.
0.23%
其他
93.61%
持股股东
持股股东
占比
Cavalry Fund I Management, LLC
2.83%
Brio Capital Management LLC
2.71%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
Melior Pharmaceuticals I, Inc.
0.23%
其他
93.61%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
5.73%
Corporation
0.56%
Individual Investor
0.39%
Investment Advisor
0.37%
Bank and Trust
0.16%
Research Firm
0.10%
Venture Capital
0.09%
Hedge Fund
0.08%
其他
92.51%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
36
46.40K
7.49%
+35.30K
2025Q1
38
272.70K
5.41%
+162.94K
2024Q4
37
258.63K
38.68%
+145.03K
2024Q3
39
166.61K
38.54%
+138.41K
2024Q2
36
78.92K
24.69%
+69.19K
2024Q1
28
31.04K
21.44%
+27.53K
2023Q4
30
32.82K
23.15%
+31.84K
2023Q3
21
574.00
6.29%
-2.15K
2023Q2
21
425.00
5.59%
-1.99K
2023Q1
22
183.00
8.18%
-2.20K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Cavalry Fund I Management, LLC
175.24K
3.47%
+175.24K
--
May 20, 2025
Brio Capital Management LLC
167.68K
3.32%
+110.57K
+193.59%
Nov 14, 2024
Abbe (Richard)
24.34K
0.48%
+24.34K
--
Jul 19, 2024
Bukwang Pharmaceutical Co., Ltd.
14.18K
0.28%
+14.18K
--
Apr 01, 2024
Melior Pharmaceuticals I, Inc.
14.18K
0.28%
+14.18K
--
Apr 01, 2024
Mercer Street Capital Partners, LLC
14.18K
0.28%
+7.93K
+126.83%
Apr 01, 2024
GAMMA Investing LLC
1.43K
0.03%
+1.43K
--
Mar 31, 2025
GS Capital Partners LLC
6.31K
0.12%
+6.31K
--
Apr 01, 2024
SBI Securities Co., Ltd.
1.00
0%
--
--
Mar 31, 2025
Ionic Ventures LLC
5.42K
0.11%
+5.33K
+5923.33%
Dec 31, 2023
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
公告日期
类型
比率
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Mar 16, 2023
Merger
4<1
Mar 16, 2023
Merger
4<1
查看更多
